29 December 2021>: Meta-Analysis
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
T A Manjunatha 1ABCDEF* , Rebecca Chng 1ABCDEF , Wai-Ping Yau 2ADEDOI: 10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
Table 5 Patient death among all included studies in which 1 or more of the treatment arms used Advagraf or Prograf.
Study | Population | Time point | Treatment arms | N | Patient death, n | Patient death, % |
---|---|---|---|---|---|---|
Anutrakulchai 2019 | ITT | 6 months | TAC BID_0.08–0.125+MPA+CS | 62 | 5 | 8.1 |
ITT | 6 months | TAC BID_0.10+MPA+CS | 63 | 1 | 1.6 | |
Arns 2017 | ITT | 6 months | TAC BID (Prograf)+MPA+CS | 38 | 1 | 2.6 |
ITT | 6 months | TAC BID (TacHexal)+MPA+CS | 35 | 0 | 0 | |
Arriola 2018 (CA) | – | 72 months | TAC BID+MPA+SRL+CS | – | – | 14.5 |
– | 72 months | TAC QD+MPA+EVR+CS | – | – | 13.4 | |
Chen 2008 | ITT | 12 months | CsA BID+SRL QD+CS | 20 | 0 | 0 |
ITT | 12 months | TAC BID+SRL QD+CS | 21 | 0 | 0 | |
Cockfield 2019 | ITT | 24 months | TAC QD_Low+ACEi/ARB | 71 | 0 | 0 |
ITT | 24 months | TAC QD_Low+OAH | 69 | 2 | 2.9 | |
ITT | 24 months | TAC QD_Std+ACEi/ARB | 71 | 0 | 0 | |
ITT | 24 months | TAC QD_Std+OAH | 70 | 1 | 1.4 | |
De Graav 2017 | ITT | 12 months | MPA+CS | 20 | 0 | 0 |
ITT | 12 months | TAC BID+MPA+CS | 20 | 1 | 5.0 | |
Ekberg 2010 (SP) | ITT | 12 months | CsA BID_Low+MPA+CS | 399 | 5 | 1.3 |
ITT | 12 months | CsA BID_Std+MPA+CS | 390 | 8 | 2.1 | |
ITT | 12 months | SRL QD_Low+MPA+CS | 399 | 6 | 1.5 | |
ITT | 12 months | TAC BID_Low+MPA+CS | 401 | 9 | 2.2 | |
Ferguson 2011 | ITT | 12 months | MPA+CS | 33 | 1 | 3.0 |
ITT | 12 months | SRL QD+CS | 26 | 0 | 0 | |
ITT | 12 months | TAC BID+MPA+CS | 30 | 0 | 0 | |
Gaston 2009 | ITT | 12 months | CNI_Low+MPA_Controlled+CS | 243 | 4 | 1.6 |
ITT | 12 months | CNI_Std+MPA_Controlled+CS | 237 | 2 | 0.8 | |
ITT | 12 months | CNI_Std+MPA_Fixed+CS | 240 | 6 | 2.5 | |
Hamdy 2008 | ITT | 36 months | SRL QD+MPA+CS | 67 | 1 | 1.5 |
ITT | 36 months | TAC BID+SRL QD+CS | 65 | 4 | 6.2 | |
Harland 2019 | FAS | Through 36 months | BLES+MPA+CS | 46 | 2 | 4.3 |
FAS | Through 36 months | TAC BID+BLES+CS | 44 | 2 | 4.5 | |
Huh 2017 | ITT | 12 months | TAC QD+MPA+CS | 75 | 0 | 0 |
ITT | 12 months | TAC QD+SRL QD+CS | 76 | 1 | 1.3 | |
Kramer 2010a | FAS | 12 months | TAC BID | 153 | 1 | 0.7 |
FAS | 12 months | TAC BID+MPA | 151 | 2 | 1.3 | |
FAS | 12 months | TAC BID+MPA+CS | 147 | 0 | 0 | |
Kramer 2010b | ITT | 12 months | TAC BID+MPA+CS | 336 | 8 | 2.4 |
ITT | 12 months | TAC QD+MPA+CS | 331 | 10 | 3.0 | |
PP | 12 months | TAC BID+MPA+CS | 291 | 3 | 1.0 | |
PP | 12 months | TAC QD+MPA+CS | 280 | 3 | 1.1 | |
Kramer 2012 (SP) | ITT | 36 months | TAC BID | 143 | 5 | 3.5 |
ITT | 36 months | TAC BID+MPA | 139 | 2 | 1.4 | |
ITT | 36 months | TAC BID+MPA+CS | 139 | 5 | 3.6 | |
Langer 2012 | ITT | 12 months | TAC BID_1.5–3 ng/mL+EVR BID+CS | 107 | 3 | 2.8 |
ITT | 12 months | TAC BID_4–7 ng/mL+EVR BID+CS | 117 | 3 | 2.6 | |
ITT | 4–12 months | TAC BID_1.5–3 ng/mL+EVR BID+CS | 107 | 2 | 2.7 | |
ITT | 4–12 months | TAC BID_4–7 ng/mL+EVR BID+CS | 117 | 1 | 1.1 | |
Liu 2015 | ITT | 15 months | CsA BID+MPA+CS | 36 | 0 | 0 |
ITT | 15 months | TAC BID+MPA+CS | 36 | 1 | 2.8 | |
Tedesco-Silva 2014 | FAS | 48 months | CsA BID+MPA+CS | 212 | 15 | 7.1 |
FAS | 48 months | TAC BID+MPA+CS | 212 | 16 | 7.5 | |
FAS | 48 months | TAC QD+MPA+CS | 214 | 13 | 6.1 | |
Tsuchiya 2013 | ITT | 12 months | TAC BID+MPA+CS | 52 | 0 | 0 |
ITT | 12 months | TAC QD+MPA+CS | 50 | 0 | 0 | |
ACEi/ARB – angiotensin-converting enzyme inhibitor/angiotensin II receptor 1 blocker; BLES – bleselumab; BID – twice daily; CA – conference abstract; CNI – calcineurin inhibitor; CS – corticosteroid; CsA – cyclosporin A; EVR – everolimus; FAS – full analysis set; ITT – intention-to-treat; MPA – mycophenolic acid; OAH – other antihypertensive; PP – per-protocol; QD – once daily; SP – secondary publication; SRL – sirolimus; Std – standard dose; TAC – tacrolimus. |